GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Baudax Bio (Baudax Bio) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.


Competitive Comparison of Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.



Baudax Bio  (OTCPK:BXRXQ) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Baudax Bio Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341